The findings of this case series suggest that most of the adverse events reported by delta-8-THC users are like those reported during acute cannabis intoxication. This finding suggests that health care professionals follow similar treatment and management protocols, and that jurisdictions should clarify whether delta-8-THC can be sold as a hemp product.
No takes yet. Share an insight, caveat, or question.
Leas et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: